Azilect (Teva Neuroscience, Inc.)
Welcome to the PulseAid listing for the Azilect drug offered from Teva Neuroscience, Inc.. This Monoamine Oxidase Inhibitor [EPC],Monoamine Oxidase Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Teva Neuroscience, Inc. |
NON-PROPRIETARY NAME: | Rasagiline Mesylate |
SUBSTANCE NAME: | RASAGILINE MESYLATE |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Monoamine Oxidase Inhibitor [EPC],Monoamine Oxidase Inhibitors [MoA] |
ROUTE: | ORAL |
DOSAGE FORM: | TABLET |
MARKETING CATEGORY NAME: | NDA |
START MARKETING DATE: | 2006-07-10 |
END MARKETING DATE: | 0000-00-00 |
Azilect HUMAN PRESCRIPTION DRUG Details:
Item Description | Azilect from Teva Neuroscience, Inc. |
LABELER NAME: | Teva Neuroscience, Inc. |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 0.5(mg/1) |
START MARKETING DATE: | 2006-07-10 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 68546-142_90b04c60-03b0-4e85-8ec3-591362f22e11 |
PRODUCT NDC: | 68546-142 |
APPLICATION NUMBER: | NDA021641 |
Other RASAGILINE MESYLATE Pharmaceutical Manufacturers / Labelers: